Key result
COVID-19 vaccination in children 5-11 links to low myopericarditis risk at ~1 case per million doses.
Why the study?
The risk of myopericarditis after COVID-19 vaccination in children aged 5 to 11 years is uncertain due to potential underreporting in existing surveillance systems.
Does COVID-19 vaccination increase the risk of myopericarditis in Danish children aged 5 to 11 years?
Does COVID-19 vaccination increase the risk of myopericarditis in Danish children aged 5 to 11 years?
This study aims to evaluate the risk of myopericarditis following COVID-19 vaccination in Danish children aged 5 to 11 years, addressing potential underreporting in existing surveillance systems.
Low reported myopericarditis risk after vaccination in US children 5-11; leaves open Danish incidence and underreporting in passive surveillance.
Myopericarditis is a severe adverse event to COVID-19 vaccines.1 The highest risk has been reported in males aged 12-29 years.2-4 According to the US Vaccine Adverse Event Reporting System (VAERS), the risk in children aged 5-11 years is low with 11 reported cases following 8.7 million doses of Pfizer-BioNTech vaccine.5 However, these numbers may be underestimated due to underreporting.6.
No takes yet. Share an insight, caveat, or question.
Nygaard et al. (2022) studied this question. Pfizer-BioNTech COVID-19 vaccination in children aged 5-11 years carries a low reported risk of myopericarditis, with 11 cases following 8.7 million doses according to US VAERS data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: